CA2348160A1 - Utilisation d'antifongiques dans le traitement des scleroses - Google Patents

Utilisation d'antifongiques dans le traitement des scleroses Download PDF

Info

Publication number
CA2348160A1
CA2348160A1 CA002348160A CA2348160A CA2348160A1 CA 2348160 A1 CA2348160 A1 CA 2348160A1 CA 002348160 A CA002348160 A CA 002348160A CA 2348160 A CA2348160 A CA 2348160A CA 2348160 A1 CA2348160 A1 CA 2348160A1
Authority
CA
Canada
Prior art keywords
fungus
genus
rodhotorula
antifungals
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002348160A
Other languages
English (en)
French (fr)
Inventor
Roumen Antonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANDIDA MEDICAL BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2348160A1 publication Critical patent/CA2348160A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002348160A 1998-10-27 1999-10-27 Utilisation d'antifongiques dans le traitement des scleroses Abandoned CA2348160A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRPCT/FR98/02302 1998-10-27
PCT/FR1998/002302 WO2000024402A1 (fr) 1998-10-27 1998-10-27 Utilisation d'antifongiques dans le traitement des scleroses
PCT/FR1999/002617 WO2000024403A1 (fr) 1998-10-27 1999-10-27 Utilisation d'antifongiques dans le traitement des scleroses

Publications (1)

Publication Number Publication Date
CA2348160A1 true CA2348160A1 (fr) 2000-05-04

Family

ID=9523370

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002348160A Abandoned CA2348160A1 (fr) 1998-10-27 1999-10-27 Utilisation d'antifongiques dans le traitement des scleroses

Country Status (8)

Country Link
EP (1) EP1124560A1 (pt)
JP (1) JP2002528064A (pt)
CN (1) CN1328466A (pt)
AU (2) AU1036999A (pt)
BR (1) BR9914792A (pt)
CA (1) CA2348160A1 (pt)
IL (1) IL142641A0 (pt)
WO (2) WO2000024402A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE753078A (fr) * 1969-07-07 1971-01-07 Schmid Inc Julius Compositions de traitement de l'hyperlipemie
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
GB2290709A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of nystatin

Also Published As

Publication number Publication date
AU1036999A (en) 2000-05-15
EP1124560A1 (fr) 2001-08-22
AU6347199A (en) 2000-05-15
WO2000024403A1 (fr) 2000-05-04
BR9914792A (pt) 2001-11-27
JP2002528064A (ja) 2002-09-03
WO2000024402A1 (fr) 2000-05-04
IL142641A0 (en) 2002-03-10
CN1328466A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
CA2119149C (fr) Medicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bacteries filamenteuses non photosynthetiques et non fructifiantes, et sa preparation
TWI495488B (zh) 用於刺激ｍａｇｐ－１以改善皮膚外觀之組合物及方法
JP5572790B2 (ja) イチイ属の形成層または前形成層由来植物幹細胞株を有効性分として含有する抗酸化、抗炎症または抗老化用組成物
EP2953611B1 (fr) Utilisation d'une composition comprenant un perséose d'avocat dans la protection des cellules souches épidermiques
FR3051116B1 (fr) Procede de production du celastrol et de derives triterpeniques pentacycliques
US20060160702A1 (en) Compositions comprising anti-proliferative agents and use thereof
EA021886B1 (ru) Выделенная фракция мастиковой смолы
EP1990404A1 (fr) Souche de trichoderma atroviride, procédé d'isolement d'une telle souche, procédé d'obtention d'un produit à base d'une telle souche et utilisation d'une telle souche
JP4227474B2 (ja) メシマコブの培養法
CA2348160A1 (fr) Utilisation d'antifongiques dans le traitement des scleroses
Parnomo et al. Test the Effectiveness of Aloe Vera Extract on the Growth of Escherichia coli in vitro
KR101936887B1 (ko) 황칠나무 추출 발효물을 유효성분으로 함유하는 육모제 조성물 및 이를 포함하는 육모제
EP3620212B1 (fr) Extrait de violette fermenté, procédé d'obtention d'un tel extrait et utilisation en cosmétique
CA1117882A (fr) Procede d'obtention d'un nouveau produit biologique et le produit en resultant
DK157035B (da) Biologisk ren mikroorganismestamme samt fremgangsmaade til fremstilling af et dyrkningsprodukt heraf til anvendelse som et hudpraeparat
Marie Elvire et al. Evaluation of the in vitro antibacterial activity of Azadirachta indica used for the treat-ment of alveolitis
FR3011008A1 (fr) Procedes d'evaluation des effets deleteres des uv sur la peau d'enfant
FR2805746A1 (fr) Procede d'augmentation d'activite anti-tumorale, composition ayant une activite anti-tumorale et procede d'evaluation d'efficacite anti-tumorale.
Wali et al. Effect of ethanol and alkaloid extract of Spirulina platensis against dermatophyte fungi
EP3965790B1 (fr) Triterpènes pentacycliques dans le traitement du vitiligo
EP3134101A1 (fr) Utilisation de cellules vegetales de bougainvillier pour l'encapsulation d'ingredients actifs
Merzouk et al. Effect of pomegranate peel extract on candida albicans growth and biofilm formation
Alkashab et al. Effects of Rosmarinus Officinalis Plant Extract on Trichomonas Vaginalis Parasites and Candida albicans under Laboratory Conditions: An Experimental Study
Dumanauw et al. The effectiveness of bilimbi extract as dental antibacterial mouthwash
RU2500413C2 (ru) Способ получения концентрата хлорофиллов из ламинарии сахаристой, обладающего антимикробным и ранозаживляющим действием

Legal Events

Date Code Title Description
FZDE Discontinued